published meta-analysis   sensitivity analysis   studies

neutralizing antibody in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsITAC, 2022 0.80 [0.42; 1.52] RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] 0.78[0.69; 0.88]ITAC, 2022, RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 202130%4,929moderatenot evaluable death or transfer to ICUdetailed resultsLopardo, 2021 0.65 [0.35; 1.22] 0.65[0.35; 1.22]Lopardo, 202110%241NAnot evaluable deathsdetailed resultsACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17] ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97] ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21] ITAC, 2022 0.80 [0.42; 1.52] Lopardo, 2021 0.57 [0.24; 1.37] RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] 0.78[0.70; 0.87]ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 2022, Lopardo, 2021, RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 202170%7,268moderatenot evaluable deaths (time to event analysis only)detailed resultsACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17] ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97] 0.74[0.55; 1.01]ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 202220%1,784moderatenot evaluable clinical improvementdetailed resultsACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20] ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29] ITAC, 2022 1.06 [0.77; 1.45] Lopardo, 2021 1.61 [0.75; 3.49] 1.07[0.97; 1.18]ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 2022, Lopardo, 202140%2,557moderatenot evaluable clinical improvement (7-day)detailed resultsACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29] ITAC, 2022 1.06 [0.77; 1.45] 0.98[0.76; 1.26]ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 202220%899moderatenot evaluable death or ventilationdetailed resultsRECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94] 0.79[0.65; 0.95]RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021234%4,280moderatenot evaluable hospital dischargedetailed resultsACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20] RECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09] 1.16[0.97; 1.39]ACTIV-3/TICO LY-CoV555 , 2020, RECOVERY (REGN-COV2), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021358%4,664moderatenot evaluable ICU admissiondetailed resultsLopardo, 2021 0.67 [0.35; 1.28] 0.67[0.35; 1.28]Lopardo, 202110%241NAnot evaluable recoverydetailed resultsACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32] ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37] ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46] 1.09[0.96; 1.25]ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 202030%1,028lownot evaluable composite safety outcome detailed resultsACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11] 1.56[0.78; 3.11]ACTIV-3/TICO LY-CoV555 , 202010%314NAnot evaluable serious adverse eventsdetailed resultsITAC, 2022 0.98 [0.66; 1.46] 0.98[0.66; 1.46]ITAC, 202210%579NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-03-29 08:50 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 729,887,742,878,975,570,771,888,1141,690,880,1255 - roots T: 290